SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot (DRB) is generating significant community excitement due to its unique association with Grok AI and its integration within the Base ecosystem. Investors are actively discussing its potential for a major market run, frequently highlighting the project's connection to AI-driven deployment and its low-follower count as an indicator of early-stage growth opportunity.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is attracting significant interest from the investment community due to its unique Directed Acyclic Graph architecture, which is positioned for enterprise and government data validation rather than standard payment processing. The conversation is currently driven by recent institutional partnerships, including collaborations with the U.S. Department of Defense and major technology players, as well as an ongoing focus on its role as scalable infrastructure for AI and secure data pipelines.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is trending following the U.S. FDA approval of VYKAT XR, the first treatment for hyperphagia in Prader-Willi syndrome, triggering significant investor interest and a sharp surge in the stock price. The community is actively discussing the drug's commercial potential, the company's future risk-reward profile, and whether this milestone makes Soleno a prime candidate for an acquisition by a larger pharmaceutical player.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high engagement as investors track the upcoming BlueBird satellite launch and broader interest in the space sector following the Artemis II mission. The community is actively debating the stock's valuation, the potential impact of competitive satellite moves, and institutional positioning ahead of a busy schedule of deployment catalysts.

Sound Group, Inc. is a global, AI-powered audio company on a mission to help people connect better and live happier. Leveraging its voice AI technologies and deep expertise in audio interaction, Sound Group is building a diverse ecosystem of intelligent audio products that cater to a global user base. By integrating technology, innovative products, and real-world data within a user-centric ecosystem, Sound Group generates a powerful growth flywheel that is driving continuous innovation and accelerating global expansion. The company was founded by Jinnan Lai and Ning Ding in 2010 and is headquartered in Singapore.

Sound Group Inc - ADR

Sound Group Inc

Sound Group Inc. is trending as investors weigh its recent record revenue growth and profitability against skepticism regarding its classification as a Chinese-linked ADR. The community is actively debating the sustainability of its dividend payouts and share repurchase programs, with bulls pointing to fundamental strength and bears questioning transparency and the potential for a sharp price correction.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing extreme volatility driven by a cycle of aggressive rhetoric from President Trump regarding Iran, followed by repeated deadline extensions and conflicting reports on potential ceasefire negotiations. Market sentiment remains fractured, with traders intensely debating the legitimacy of these headlines as they navigate a landscape of high oil prices, geopolitical risk, and the impact of the ongoing conflict on tech and data-centric sectors.

General Mills, Inc. engages in the manufacture and marketing of branded consumer foods sold through retail stores. Its product categories include snacks, ready-to-eat cereal, convenient meals, pet food, refrigerated and frozen dough, baking mixes and ingredients, yogurt, and ice cream. It operates through the following segments: North America Retail, International, North America Pet, and North America Foodservice. The North America Retail segment includes grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, convenience stores, and e-commerce grocery providers. The International segment refers to the retail and foodservice businesses outside of the US and Canada. The North America Pet segment includes pet food products sold in national pet superstore chains, e-commerce retailers, grocery stores, regional pet store chains, mass merchandisers, and veterinary clinics and hospitals. The North America Foodservice segment offers ready-to-eat cereals, snacks, refrigerated yogurt, frozen meals, unbaked and fully baked frozen dough products, baking mixes, and bakery flour. The company was founded by Cadwallader C. Washburn on June 20, 1928 and is headquartered in Minneapolis, MN.

General Mills, Inc.

General Mills is currently under investor scrutiny as the market weighs disappointing revenue trends against its status as a high-yield defensive play. While some investors are accumulating shares to capitalize on the dividend, sentiment remains mixed as traders debate whether the stock is a value trap or an oversold opportunity heading into earnings.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened market attention driven by a combination of high-profile collaborations with industry leaders like NVIDIA and Google, as well as a series of mission-critical contracts for its quantum timing and sensor technology. While the community remains divided over short-term price volatility and the typical challenges faced by post-SPAC entities, investors are actively debating the company's long-term potential as a critical player in the evolving quantum infrastructure and national security landscape.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently a major topic of debate among traders who are actively weighing the impact of potential regulatory milestones, like the Clarity Act, against concerns over institutional inflows and broader market volatility. While some participants are aggressively accumulating during price dips, citing the project's real-world asset tokenization capabilities and enterprise partnerships, others remain cautious due to persistent selling pressure and comparisons to Bitcoin's dominant price action.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its expanding role as critical decentralized infrastructure, bolstered by recent integrations like Cardano and its selection by the U.S. Department of Commerce for on-chain economic data. The community is actively discussing the protocol's institutional-grade revenue model, including its token buyback program, while positioning it as a foundational player in the Real World Asset (RWA) market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% Higher - Time to Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 11.6% - Here's Why...

Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC)

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) was the target of unusually large options trading activity on Thursday. Stock traders purchased 2,266 call options on the stock. This is an...

HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC)

HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Oric Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>Jones Research maintained a ‘Buy’ rating on the stock with a $25 price target, according to The Fly.</li><li>Wedbush Securities lowered its price target to $17 from $20 but maintained an ‘Outperform’ rating.</li><li>Cantor Fitzgerald said Rinzimetostat’s efficacy appears comparable to competitor Mevrometostat from Pfizer</li></ul>Shares of Oric Pharmaceuticals (ORIC) plunged 28% on Wednesday as investors reacted to tolerability concerns tied to a higher dose of its prostate cancer drug, even as analysts said the sharp sell-off appears exaggerated.<a href="https://stocktwits.com/symbol/ORIC">ORIC shares</a> recorded their biggest intraday slump in more than four years.<h2 class="st-heading-2">Oric Selects 400 MG Dose Of Rinzimetostat</h2>On Tuesday, Oric <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">announced</a> it selected a lower 400 mg dose of its investigational drug Rinzimetostat. In the Phase 1 trial involving patients with metastatic castration-resistant prostate cancer, the 600 mg dose showed a higher rate of side effects, dose interruptions, and discontinuations when combined with darolutamide.By contrast, the 400 mg dose demonstrated a more manageable safety profile, with mostly mild side effects and only limited severe (Grade 3) events. The company now plans to move forward with the lower dose in a global Phase 3 trial in the first half of 2026.<h2 class="st-heading-2">Analysts Say Selloff is Exaggerated</h2>Despite the sharp selloff, analysts suggest the reaction may be overdone. Jones Research noted that the data appears broadly in line with Pfizer’s competing drug Mevrometostat, while potentially offering a better safety profile, according to The Fly.The firm said the selloff ‘appears exaggerated,” pointing out that Oric’s data is still early, with only about five months of follow-up compared to nine to 10 months for Pfizer’s results. Jones &nbsp;Research maintained a ‘Buy’ rating on the stock with a $25 price target.Other firms, including Cantor Fitzgerald and Wedbush, highlighted that efficacy remains comparable. “Efficacy appears comparable to competitor Mevrometostat from Pfizer, with Rinzi showing a potentially better safety profile,” Cantor said. It has an ‘Overweight’ rating on Oric shares.<h2 class="st-heading-2">Wedbush Says Results broadly In Line With Pfizer’s Drug</h2>Meanwhile, David Nierengarten of Wedbush Securities lowered his price target to $17 from $20 while maintaining an ‘Outperform’ rating. The analyst said Oric’s Phase 1 prostate cancer results are broadly in line with Pfizer’s, even though Oric tested its drug in a sicker patient group.He added that while greater efficacy differences are ideal, better tolerability is important, especially for older patients on long-term treatment, and could influence doctors’ choices if both drugs are similarly effective.Despite the sharp selloff, retail sentiment turned ‘extremely bullish’ from ‘neutral’ a day earlier.One user said the stock has "really good upside potential"<stembedurl>http://stocktwits.com/LF5/message/649195078</stembedurl>The stock has gained more than 10% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/oric-falls-after-hours-on-safety-concerns-around-prostate-cancer-candidate/cZ7HT8GRIVz">ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Oric Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Oric shares tanked after the firm selected a lower 400 mg dose of its investigational drug for prostate cancer after its 600 mg dose showed a higher rate of side effects.

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says ‘Selloff Appears Exaggerated’

Equity

What's Behind The Drop In Oric Pharmaceuticals Stock Today?

Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients...

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade...

Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush

Wedbush dropped their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Wednesday...

Futures, Bonds Surge On Optimism War May End, Oil Tumbles Below $100

Futures, Bonds Surge On Optimism War May End, Oil Tumbles Below $100 Futures and bonds jump and oil fell, sending Brent briefly below $100 a barrel, as the de-escalation/technical/macro led relief...

Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.read more...

ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?

ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3 trial, before falling sharply in after-hours trading.read more...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$8.89
Prev Close	$7.48
Open	$7.25
Dividend Yield	0.00%
50-Day Moving Average	$11.60
Beta	1.43
Avg. Volume	1.62M
PE Ratio	-5.87

52-Week High	$14.93
52-Week Low	$3.90
Market Capitalization	$892.18M
EPS (Annual)	-$1.47
Price to Book	2.28
Revenue Per Employee	$0.00

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORIC News

ORICORIC Pharmaceuticals Inc